Recombinant Mycobacterium bovis UPF0060 membrane protein BCG_2666c (BCG_2666c)

What is the structural characterization of Mycobacterium bovis BCG_2666c protein?

Mycobacterium bovis BCG_2666c is classified as a UPF0060 membrane protein found in the Mycobacterium bovis strain BCG/Pasteur 1173P2. The protein consists of 110 amino acids in its recombinant form commonly used in research settings. As a membrane protein, BCG_2666c features hydrophobic domains that facilitate integration into cellular membranes, which presents specific challenges for expression and purification .

The three-dimensional structure has not been fully resolved through crystallography, though computational prediction models suggest a predominant alpha-helical secondary structure consistent with its membrane-spanning function. Researchers should note that the membrane localization impacts experimental design considerations for both expression systems and downstream applications.

What expression systems are most effective for producing recombinant Mycobacterium bovis BCG_2666c?

Several expression systems have demonstrated efficacy for BCG_2666c production, each with distinct advantages:

When selecting an expression system, researchers should consider:

• The intended application (structural vs. functional studies)

• Required protein yield

• Importance of post-translational modifications

• Resource availability and timeline constraints

For initial characterization studies, E. coli systems often provide sufficient yield and purity, while applications requiring authentic protein conformation may necessitate mammalian expression systems despite their higher cost and complexity .

How does BCG_2666c relate to tuberculosis pathogenesis and vaccine development?

While direct evidence linking BCG_2666c to tuberculosis pathogenesis remains limited, its membrane localization suggests potential roles in:

• Host-pathogen interactions at the bacterial surface

• Nutrient acquisition or export of virulence factors

• Signaling processes during infection

• Maintaining cell wall integrity under stress conditions

For vaccine development, membrane proteins like BCG_2666c represent attractive targets due to their accessibility to the immune system. The research community has identified several advantages to considering BCG_2666c in vaccine development approaches:

• As a membrane protein, it may elicit stronger antibody responses than cytoplasmic proteins

• Its conservation across mycobacterial species could potentially provide cross-protection

• Recombinant forms can be produced without requiring cultivation of pathogenic mycobacteria

• It can be incorporated into various vaccine platforms including protein subunit and vector-based approaches

How can researchers effectively design studies to evaluate the immunogenicity of BCG_2666c for potential tuberculosis vaccine applications?

Designing robust immunogenicity studies for BCG_2666c requires a systematic approach that evaluates both humoral and cell-mediated immune responses. A comprehensive evaluation should include:

1. Antigen Preparation Considerations:

• Compare different expression systems to identify preparations that maintain conformational epitopes

• Evaluate both full-length BCG_2666c and immunodominant peptide fragments

• Consider different adjuvant formulations optimized for mycobacterial antigens

• Implement quality control measures to ensure batch consistency through physicochemical characterization

2. In Vitro Immunological Assays:

• T-cell stimulation assays using PBMCs from:

  • BCG-vaccinated individuals

  • TB patients (active and latent)

  • Healthy controls from endemic and non-endemic regions

• Measure cytokine profiles (IFN-γ, TNF-α, IL-2, IL-17) through ELISpot and intracellular cytokine staining

• Assess antibody responses via ELISA, including subclass distribution and avidity measurements

• Evaluate B-cell epitope mapping through peptide arrays or phage display

3. Animal Model Testing Protocol:
The following workflow represents a methodologically sound approach:

4. Correlates of Protection Analysis:

• Identify specific immune signatures associated with protection

• Perform systems biology approaches (transcriptomics, proteomics) to characterize response networks

• Establish thresholds for protective immunity to guide vaccine formulation optimization

• Compare results with established TB vaccine candidates to benchmark performance

When designing these studies, researchers should incorporate appropriate controls including:

• Empty vector or irrelevant protein controls

• BCG vaccine positive control

• Multiple antigen delivery platforms (protein-in-adjuvant, viral vectors, DNA vaccines)

This methodological framework enables systematic evaluation of BCG_2666c's potential as a TB vaccine component while generating mechanistic insights into protective immunity.

How does the comparative analysis of BCG_2666c with homologs in other mycobacterial species inform evolutionary and functional understanding?

1. Phylogenetic Analysis Protocol:

• Extract UPF0060 membrane protein sequences from diverse mycobacterial genomes

• Perform multiple sequence alignment using MUSCLE or MAFFT algorithms

• Construct maximum likelihood phylogenetic trees with appropriate evolutionary models

• Analyze selection pressure using dN/dS ratios to identify conserved functional domains

• Create visualization of evolutionary relationships with annotation of pathogenic vs. non-pathogenic species

Evolutionary Conservation Table:

2. Structure-Function Correlation:

• Map conserved residues onto predicted structural models

• Identify conservation patterns in transmembrane vs. loop regions

• Correlate conserved motifs with predicted functional domains

• Compare with structurally characterized homologs in other bacterial families

3. Genomic Context Analysis:

• Examine operonic organization across species

• Identify conserved gene neighborhoods suggesting functional relationships

• Analyze promoter regions for conserved regulatory elements

• Evaluate horizontal gene transfer patterns through GC content and codon usage analysis

4. Transcriptional Response Comparison:

• Compile expression data from multiple mycobacterial species

• Compare expression profiles under similar stress conditions

• Identify conserved vs. species-specific regulatory patterns

• Create co-expression networks to infer functional associations

This comparative approach allows researchers to:

• Identify residues essential for core functions versus those involved in species-specific adaptations

• Predict functional roles based on conservation patterns

• Understand evolutionary pressures that have shaped BCG_2666c

• Determine the potential of BCG_2666c as a broad-spectrum or species-specific drug target

The strong conservation of BCG_2666c across pathogenic mycobacteria, particularly within transmembrane domains, suggests an important functional role that has been maintained throughout mycobacterial evolution, making it a potentially valuable target for further investigation in tuberculosis research .

What are the optimal protocols for expressing and purifying recombinant BCG_2666c for structural studies?

Obtaining high-quality recombinant BCG_2666c suitable for structural studies requires specialized protocols that address the challenges inherent to membrane proteins. The following methodology has been optimized based on research experience:

Expression System Selection and Optimization:

For structural studies, E. coli remains the preferred initial system due to its high yield potential and established protocols for membrane protein expression. The recommended workflow includes:

• Construct Design:

  • Clone the BCG_2666c gene with an N-terminal His10 tag and a C-terminal FLAG tag

  • Include a TEV protease cleavage site after the His tag

  • Consider fusion partners such as MBP or SUMO to enhance solubility

  • Optimize codon usage for E. coli expression

• Protein Quality Assessment:

  • Analytical SEC to determine monodispersity

  • Circular dichroism to verify secondary structure

  • Thermal stability assays using differential scanning fluorimetry

  • Mass spectrometry to confirm protein identity and integrity

  • Negative stain electron microscopy to verify homogeneity

For crystallization trials, the protein should be concentrated to 10-15 mg/ml in buffer containing 0.02-0.05% DDM or exchanged into facial amphiphiles or nanodiscs to enhance crystallization propensity. Alternative approaches like lipidic cubic phase crystallization have shown success with mycobacterial membrane proteins of similar size .